HUMA
Humacyte, Inc. · Healthcare
Insiders bought $50K of Humacyte, Inc. in the last 12 months
1 insider bought on 1 day.
HUMA over the last year
Largest buyers, last 12 months
HUMA after insider buys
3 months after each buy, from the first price a copier could get.
9 buys since 2021 with 3 months of prices.
Every filing
55 insider filings since 2021, newest first
Kathleen Sebelius · Director
Dale A. Sander · CFO and Chief Corp. Dev. Off
Shamik J Parikh · Chief Medical Officer
Dale A. Sander · CFO, Chief Corp. Deve. Officer
Kathleen Sebelius · Director
Laura E Niklason · President, CEO and Director
Brady W Dougan · Director
Kathleen Sebelius · Director
Brady W Dougan · Director
Laura E Niklason · President, CEO and Director
Brady W Dougan · Director
Laura E Niklason · President, CEO and Director
Dale A. Sander · CFO, Chief Corp. Deve. Officer
Laura E Niklason · President, CEO and Director
Brady W Dougan · Director
Brady W Dougan · Director
Laura E Niklason · President, CEO and Director
Heather Ledbetter Prichard · COO
Max N. Wallace · Director
Gordon M Binder · Director
Laura E Niklason · President, CEO and Director
Brady W Dougan · Director
Laura E Niklason · President, CEO and Director
Brady W Dougan · Director
Ayabudge LLC · 10% owner
Ayabudge LLC · 10% owner
Brady W Dougan · Director and 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Brady W Dougan · Director and 10% owner
Ayabudge LLC · 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Heather Ledbetter Prichard · COO
Brady W Dougan · Director and 10% owner
Ayabudge LLC · 10% owner
Dale A. Sander · CFO, Chief Corp. Deve. Officer
Ayabudge LLC · 10% owner
Brady W Dougan · Director and 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Brady W Dougan · Director and 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Brady W Dougan · Director and 10% owner
Ayabudge LLC · 10% owner
Ayabudge LLC · 10% owner
Brady W Dougan · Director and 10% owner
Laura E Niklason · President, CEO, Director and 10% owner
Gordon M Binder · Director
Gordon M Binder · Director
Brady W Dougan · Director and 10% owner
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.